Novocure (NVCR) Announces Pivotal LUNAR Study in Non-Small Cell Lung Cancer Met Primary Overall Survival Endpoint

Go back to Novocure (NVCR) Announces Pivotal LUNAR Study in Non-Small Cell Lung Cancer Met Primary Overall Survival Endpoint

Novocure (NVCR) Climbs 70% After Pivotal LUNAR Study in NSCLC Met Primary Overall Survival Endpoint

January 5, 2023 7:10 AM EST

Novocure (NASDAQ: NVCR) Climbs 70% After Pivotal LUNAR Study in NSCLC Met Primary Overall Survival Endpoint

... More